Oscotec and KT&G jointly to develop osteoporosis drugs.

Oscotec and KT&G agreed for a joint development of OPG secretion stimulant, a new drug candidate for the treatment of osteoporosis and arthritis, and to assign its preclinical test to Quintiles, a UK clinical research company, some times during the first half of 2006.

OPG (osteoprotegerin) is a protein secreted by the osteoblast, a bone forming cell, which regulates a differentiation of oste...